EyePoint doses first patient in Phase 2 VERONA trial of EYP-1901 for DME

EyePoint, Inc.

EYP-1901 (vorolanib/Durasert E) enters Phase 2 for diabetic macular edema; ~25 patients to be enrolled.
Primary endpoint: time to first supplemental aflibercept injection up to 24 weeks.
Topline data from VERONA expected in Q1 2025; PAVIA NPDR data due Q2 2024.
First Phase 3 pivotal trial in wet AMD anticipated to start in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.